JonesTrading analyst Soumit Roy maintained a Buy rating on Rain Therapeutics (RAIN – Research Report) today and set a price target of $20.00. The company’s shares opened today at $9.98.
Roy covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, Aeglea Biotherapeutics, and Rain Therapeutics. According to TipRanks, Roy has an average return of 3.8% and a 31.85% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rain Therapeutics with a $18.33 average price target, representing an 83.67% upside. In a report released today, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $18.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Rain Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $18.04 million. In comparison, last year the company had a GAAP net loss of $18.43 million
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RAIN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rain Therapeutics Inc is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which they are able to genetically select patients they believe will most likely benefit. Its lead product candidate, RAIN-32 is a small molecule, oral inhibitor of mouse double minute 2, which is oncogenic in numerous cancers.
Read More on RAIN:
- Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology
- Rain Oncology initiated with a Buy at EF Hutton
- Rain Therapeutics Inc. Announces Name Change to Rain Oncology Inc.
- Rain Therapeutics announces name change to Rain Oncology
- Rain Therapeutics to Participate in the 41st Annual J.P. Morgan Health Care Conference
